// App-Quantinova.ai

TPS1117 : NRG-BR002: A phase IIR/III trial of standard of care therapy with or without stereotactic body radiotherapy (SBRT) and/or surgical ablation for newly oligometastatic breast cancer (NCT02364557).

Researchers

Presenter

  • Steven J. Chmura

Principal Investigators

  • Kathryn A. Winter

  • Hania A Al-Hallaq

  • Virginia F. Borges

  • Nora T. Jaskowiak

  • Martha Matuszak

  • Michael T. Milano

  • Joseph Kamel Salama

  • Wendy A. Woodward

  • Julia R. White

Medical Centers

  • The University of Chicago Medical Center, Chicago, IL

  • Statistical Center, Radiation Therapy Oncology Group, Philadelphia, PA

  • The University of Chicago Medical Center, Chicago, IL

  • University of Colorado Cancer Center, Aurora, CO

  • The University of Chicago Medical Center, Chicago, IL

  • University of Michigan, Ann Arbor, MI

  • University of Rochester Medcal Center, Rochester, NY

  • Duke University Medical Center, Durham, NC

  • Department of Bioinformatics, The University of Texas MD Anderson Cancer Center, Houston, TX

  • NRG Oncology/RTOG, and The Ohio State University Comprehensive Cancer Center, Columbus, OH

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • Circulating tumor cells

  • erb-b2 receptor tyrosine kinase 2

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Controlled

Phase

  • II

Study Id's

  • NCT02364557

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved